|Articles|June 5, 2017
Evoke Pharma Enters Agreement with Rho CRO to Submit NDA
Advertisement
Evoke Pharma, Inc.-a pharma company focused on treatments for gastrointestinal diseases-announced an agreement with Rho, Inc.-a regulatory consulting and contract research organization (CRO).
Rho and Evoke will collaborate with the preparation and submission of Evoke's planned 505(b)(2) New Drug Application (NDA) for Gimoti™-the company’s nasal delivery formulation of metoclopramide, which helps relieve symptoms associated with acute and recurrent diabetic gastroparesis in adult women.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Survey Finds US Biotechs Prefer Domestic First-in-Human Trials but FDA Hurdles Are Pushing Them Abroad
2
ACT Brief: Data Quality as Foundational to Trial Modernization, CRAs Evolving to Strategic Site Partners, and 2026 Emerging Pharma Leaders Announced
3
Tufts CSDD Analysis Finds AI Clinical Monitoring Agent Can Generate Up to $21 Million in Net Financial Value Per Drug Development Program
4
ACT Brief: Training Completion Versus Execution Readiness, AI Monitoring Agent Financial Value at Scale, and FDA Warning Letters and AI Oversight Gaps
5